Phase 3 TIDES trial

Potential Impact of Takeda’s Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results

− Takeda’s dengue vaccine candidate (TAK-003) prevented 83.6% of hospitalizations and 62.0% of dengue illness overall, with no identified important…

Read More »